Which has grown faster, GYRE or MLAB?

Over the past five years, GYRE grew revenue faster — GYRE at a 84.92% CAGR versus MLAB at 12.45%.

Does GYRE or MLAB pay a bigger dividend?

MLAB pays a dividend (0.45% yield), while GYRE is a former payer with no current dividend run rate.

Is GYRE or MLAB more profitable?

MLAB runs the higher net margin — GYRE at -14.52% versus MLAB at 1.92%.

How have GYRE and MLAB total returns compared?

Over the past 10 years, GYRE delivered -14.92% and MLAB delivered 2.29% annualized total return. Past performance doesn't predict future results.

Gyre Therapeutics, Inc. (GYRE) vs Mesa Laboratories, Inc. (MLAB)

A side-by-side comparison of Gyre Therapeutics, Inc. and Mesa Laboratories, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

GYRE

Gyre Therapeutics, Inc.

$789M

$7.08HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

MLAB

Mesa Laboratories, Inc.

$761M

$136.06HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — GYRE vs MLAB

growth of $100 · dividends reinvested · last 10y

GYRE -79.5% (-14.6%/yr)MLAB +27.4% (+2.4%/yr)MLAB compounded faster over this window

Log scale — wide-divergence pair

GYRE MLAB

GYRE vs MLAB: by the numbers

•GYRE is the larger company ($789M vs $761M market cap).
•MLAB is profitable (1.92% net margin) while GYRE runs a net loss (-14.52%).
•GYRE grew revenue faster over the past five years (84.92% vs 12.45% CAGR).
•MLAB pays a dividend (0.45% yield), while GYRE is a former payer with no current dividend run rate.

Metrics side by side

Valuation

Metric	GYRE	MLAB
P/E ratio	N/A	161.98
PEG ratio	N/A	11.92
P/S ratio	6.61	3.05
P/B ratio	7.31	4.03
EV / EBITDA	N/A	18.31
FCF yield	N/A	6.94%

Profitability

Metric	GYRE	MLAB
Gross margin	94.30%	65.99%
Operating margin	9.86%	9.00%
Net margin	-14.52%	1.92%
ROE	-13.30%	2.54%
ROIC	-9.77%	3.29%

Dividends

Metric	GYRE	MLAB
Dividend yield	N/A	0.45%
Payout ratio	N/A	76.19%

Growth (annualized)

Metric	GYRE	MLAB
Revenue CAGR (5Y)	84.92%	12.45%
EPS CAGR (5Y)	N/A	13.08%
FCF CAGR (5Y)	N/A	4.63%
Total return CAGR (5Y)	-0.34%	-13.52%

Frequently asked

Which has grown faster, GYRE or MLAB?: Over the past five years, GYRE grew revenue faster — GYRE at a 84.92% CAGR versus MLAB at 12.45%.
Does GYRE or MLAB pay a bigger dividend?: MLAB pays a dividend (0.45% yield), while GYRE is a former payer with no current dividend run rate.
Is GYRE or MLAB more profitable?: MLAB runs the higher net margin — GYRE at -14.52% versus MLAB at 1.92%.
How have GYRE and MLAB total returns compared?: Over the past 10 years, GYRE delivered -14.92% and MLAB delivered 2.29% annualized total return. Past performance doesn't predict future results.

Go deeper

Full GYRE analysis Full MLAB analysis Interactive comparison tool

Dig into the metrics

Mesa Laboratories P/E ratio Mesa Laboratories dividend yield Gyre Therapeutics ROE Mesa Laboratories ROE Gyre Therapeutics operating margin Mesa Laboratories operating margin Gyre Therapeutics revenue growth Mesa Laboratories revenue growth Gyre Therapeutics free cash flow Mesa Laboratories free cash flow

Gyre Therapeutics & Mesa Laboratories appear in these rankings

Fastest Revenue Growth Stocks Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.